Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial.

Chunyan LanJingxian ShenYin WangJundong LiZhimin LiuMian HeXinping CaoJiayu LingJiaming HuangMin ZhengGuorong ZouHaowen YanQing LiuFan YangWei WeiYan-Hong DengYing XiongXin Huang

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)

Camrelizumab plus apatinib had promising antitumor activity and manageable toxicities in patients with advanced cervical cancer. Larger randomized controlled trials are warranted to validate our findings.

Keyphrases

open label
randomized controlled trial
clinical trial
phase ii
study protocol
phase ii study
phase iii
cross sectional
systematic review